The Haemair team consist of capable well-qualified engineers and
medical devices from R&D to production and full commercialization.
Haemair was founded in 2005 by engineers with close relatives who had suffered and died of lung disease.
From the outset, the vision was of a device that would directly oxygenate blood to augment residual lung capacity and ultimately provide an alternative to lung transplant.
In over ten years, the company has attracted investment of over £3million from a core group who hope ultimately to gain a return on their investment, but whose primary motivation is to help lung-disease sufferers and their families.
The Company moved to the Swansea University site in 2006 in order to benefit from the world-leading research in blood rheology coming from the collaboration between the Engineering and Medical Schools.
The improvements incorporated in our innovative design have already attracted the interest of a major multinational medical device company with whom we now have a distribution contract to cover the whole of the European Economic Area and Canada.
We are currently establishing a manufacturing facility designed to meet our needs for 3 to 4 years.
Haemair Ltd
The initial Haemair innovation is a development of established Extracorporeal Life Support (ECLS/ECMO) technology used to assist patients with reversible life threatening respiratory or cardiac disease for periods days or even weeks.
Haemair was founded by engineers with close relatives who had suffered and died of lung disease. From the outset, the vision was of a device that would directly oxygenate blood to augment residual lung capacity and ultimately provide an alternative to lung transplant.
Haemair won the Innovation category at the Evening Post/Swansea Bay Business Life Awards that took place in Brangwyn Hall, Swansea on 3rd March 2016.
The company holds relevant granted patents for these innovative developments.
The initial Haemair product is a development of established Extracorporeal Life Support (ECLS/ECMO) technology and will be used to treat patients recovering from:
